Featuring perspectives from Prof Solange Peters and Dr Joshua K Sabari, including the following topics:

• Introduction (0:00)
• Best Option for Your Patient (1:28)
• Biological Considerations (6:26)
• KRAS G12C Inhibitors (11:33)
• Second-Line Treatment (13:02)
• Current Clinical Trials in the First-Line Metastatic Setting (32:18)
• Current Clinical Trials in the Localized Setting (49:52)
• Current Clinical Trials with New Treatment Combinations and Agents (53:51)

CME information and select publications

Featuring perspectives from Dr William K Oh and Dr Mary-Ellen Taplin, including the following topics:

• Introduction: Another Perspective on the Treatment of Localized Prostate Cancer (0:00)
• Nonmetastatic Disease (10:32)
• Metastatic Androgen Pathway Modulation-Naïve and Androgen Pathway Modulation-Sensitive Disease (41:50)

CME information and select publications

Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:

• Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic lymphocytic leukemia (CLL) with an SF3B1 mutation and autoimmune hemolytic anemia receives acalabrutinib/venetoclax/obinutuzumab (0:00)
• Case: A man in his late 60s with bulky CLL diagnosed abroad receives zanubrutinib monotherapy (12:48)
• Case: A man in his late 40s with IGHV-mutated, del(13q) CLL with worsening symptoms and diffuse adenopathy after 1 year of observation receives venetoclax/obinutuzumab and attains a complete response (21:29)

CME information and select publications

Featuring perspectives from Prof John Seymour, including the following topics:

• Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00)
• Venetoclax re-treatment and ongoing trials with acalabrutinib/venetoclax for CLL (6:21)
• First-line treatment with sonrotoclax and zanubrutinib for CLL (13:10)

CME information and select publications

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics:

• Tolerability of capivasertib and management of associated side effects — Question from Neeraj Agarwal, MD, FASCO (0:00)
• Case: A man in his early 70s with Type 2 diabetes presents with metastatic hormone-sensitive prostate cancer with widespread bone metastases and PTEN deficiency on next-generation sequencing and receives relugolix/darolutamide — Rana R McKay, MD, FASCO (8:39)

CME information and select publications

Featuring perspectives from Dr Lisa A Carey and Dr Maha Hussain, including the following topics:

• Introduction (0:00)
• HER2 History (1:32)
• Cases from the GMO Survey (7:06)
• Biology and Selection of First-Line Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer (mBC) — Dr Mahtani (19:56)
• Faculty Case Presentations (31:37)
• Patterns of Care Survey — Part 1 (38:26)
• Optimizing the Use of Up-Front Maintenance Therapy for HER2-Positive mBC — Dr Carey (44:53)
• Faculty Case Presentations (54:13)

CME information and select publications

Featuring perspectives from Dr William G Wierda, including the following topics:

• Introduction: Overview of the Grand Rounds Chronic Lymphocytic Leukemia Initiative (0:00)
• Sequencing Road Map (12:39)
• Key Datasets — Pirtobrutinib (21:08)
• Investigator Survey (34:09)
• Chimeric Antigen Receptor T-Cell Therapy (45:08)
• Other Novel Therapy Approaches (49:58)
• EHA 2026 (54:45)

CME information and select publications

Featuring an interview with Prof Ticiana Leal, including the following topics:

• Pathophysiology and clinical signs and symptoms (0:00)
• Screening and/or diagnostic approaches (5:45)
• Potential impact of available therapies for small cell lung cancer (SCLC) on paraneoplastic syndromes (7:36)
• Key clinical trial data for amifampridine and practicalities of its administration (14:05)
• Building awareness among patients, caregivers and the oncology community (22:37)
• Role of pyridostigmine in managing Lambert-Eaton myasthenic syndrome (LEMS); potential integration of EMG (electromyography) into monitoring (25:35)
• Case: A man in his early 70s who receives a diagnosis of limited-stage SCLC (LS-SCLC) with LEMS and undergoes treatment (27:41)
• Case: A woman in her late 70s already diagnosed with LS-SCLC who is subsequently evaluated and treated for LEMS (37:55)
• Current research and potential developments in the treatment of SCLC (48:32)

CME information and select publications

Featuring perspectives from Mr Michael Lai, Dr Scott T Tagawa, Ms Stacy E Walker and Dr Evan Y Yu, moderated by Dr Tagawa, including the following topics:

• Introduction (0:00)
• Overview of Prostate Cancer (3:00)
• Hormonal Therapy for Nonmetastatic and Metastatic Hormone-Sensitive Prostate Cancer (HSPC) (6:12)
• Potential Role of Capivasertib in Metastatic HSPC (27:22)
• Current and Potential Future Role of PARP Inhibitors in Metastatic PC (46:39)
• Current and Future Role of Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic PC (1:09:14)

CME information and select publications

Featuring perspectives from Prof Peter Schmid and Dr Melinda Telli, including the following topics:

• Introduction: TROP2-Targeting Antibody-Drug Conjugates (ADCs) for Metastatic Triple-Negative Breast Cancer (0:00)
• First-Line Therapy (PD-L1 Negative) (6:53)
• First-Line Therapy (PD-L1 Positive) (23:40)
• Second-Line Therapy (Sequencing) (34:08)
• Adverse Events with TROP2-Targeting ADCs (43:43)

CME information and select publications